CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD COSTS IN THE NETHERLANDS

被引：0
|
作者：
van Gils, C. W. M. [1 ]
de Groot, S. [1 ]
Redekop, W. K. [1 ]
Uyl-De Groot, C. A. [1 ]
机构：
[1] Inst Med Techonol Assessment, Rotterdam, Netherlands
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1207
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A453 / A453
页数：1
相关论文
共 50 条
  • [31] NALIRIFOX (iposomal irinotecan+5-fluorouracil/feucovorin plus oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin plus oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
    O'Reilly, E.
    Li, J.
    DerSarkissian, M.
    Chang, R.
    Cheng, M.
    Yu, L.
    Rane, D.
    Zhang, L.
    Xiao, Z.
    Benzaghou, F.
    Duh, M.
    Chen, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S83 - S83
  • [32] A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
    Gravalos, Cristina
    Salut, Antonieta
    Garcia-Giron, Carlos
    Garcia-Carbonero, Rocio
    Isabel Leon, Ana
    Sevilla, Isabel
    Maurel, Joan
    Esteban, Beatriz
    Garcia-Rico, Eduardo
    Murias, Adolfo
    Cortes-Funes, Hernan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (08): : 606 - 612
  • [33] A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
    Cristina Gravalos
    Antonieta Salut
    Carlos García-Girón
    Rocío García-Carbonero
    Ana Isabel León
    Isabel Sevilla
    Joan Maurel
    Beatriz Esteban
    Eduardo García-Rico
    Adolfo Murias
    Hernán Cortés-Funes
    Clinical and Translational Oncology, 2012, 14 : 606 - 612
  • [34] Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
    Peng, Jingyuan
    Tang, Chongqing
    Zeng, Xiaohui
    Liu, Shikun
    PLOS ONE, 2018, 13 (06):
  • [35] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Jeong Eun Kim
    Yong Sang Hong
    Hwa Jung Kim
    Kyu-pyo Kim
    Sun Young Kim
    Seok-Byung Lim
    In Ja Park
    Chan Wook Kim
    Yong Sik Yoon
    Chang Sik Yu
    Jin Cheon Kim
    Ji Hun Kim
    Tae Won Kim
    Annals of Surgical Oncology, 2017, 24 : 1289 - 1294
  • [36] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Hwa Jung
    Kim, Kyu-pyo
    Kim, Sun Young
    Lim, Seok-Byung
    Park, In Ja
    Kim, Chan Wook
    Yoon, Yong Sik
    Yu, Chang Sik
    Kim, Jin Cheon
    Kim, Ji Hun
    Kim, Tae Won
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) : 1289 - 1294
  • [37] Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage Ⅲ colon cancer: A meta-analysis
    Hong-Tao Fu
    Ying-Ying Xu
    Jing-Jing Tian
    Jia-Xin Fu
    Shao-Ling Nie
    Yan-Yan Tang
    Ping Chen
    Liang Zong
    World Journal of Meta-Analysis, 2020, 8 (01) : 27 - 40
  • [38] Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
    Nakayama, Goro
    Takano, Nao
    Taniguchi, Hiroya
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Teramoto, Hitoshi
    Hashimoto, Ryoji
    Sakai, Mitsuru
    Ishiyama, Akiharu
    Kinoshita, Takashi
    Hayashi, Naomi
    Nakamura, Masanori
    Hattori, Norifumi
    Sato, Yusuke
    Umeda, Shinichi
    Uehara, Kei
    Aiba, Toshisada
    Sonohara, Fuminori
    Hayashi, Masamichi
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Murotani, Kenta
    Ando, Masahiko
    Ando, Yuichi
    Muro, Kei
    Kodera, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 61 - 71
  • [39] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin - A prospective analysis
    Kuebler, J. Philip
    Colangelo, Linda
    O'Connell, Michael J.
    Smith, Roy E.
    Yothers, Greg
    Begovic, Mirsada
    Robinson, Bridget
    Seay, Thomas E.
    Wolmark, Norman
    CANCER, 2007, 110 (09) : 1945 - 1950
  • [40] Pilot study of the combination of capecitabine plus oxaliplatin as adjuvant therapy for patients with stage III and high risk stage II colon cancer
    Olier, C.
    Reyna, C.
    Aramendia, J. M.
    Rodriguez, J.
    Viudez, A.
    Chopitea, A.
    Garcia-Foncillas, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345